MaaT Pharma H1 operating loss widens 29% to EUR 19 million; revenue drops 55% to EUR 1.08 million

• MaaT Pharma posted H1 2026 revenue down 56% to EUR 1.08 million, while net loss widened 22% to EUR 18.33 million.
• R&D expenses climbed 30% to EUR 19.2 million, while operating loss widened 29% to EUR 19 million.
• Cash and cash equivalents fell to EUR 17.1 million at June 30, 2026, from EUR 24.9 million at Dec. 31, 2025.
• Management said cash-preservation measures extend its cash runway to December 2026, and it is exploring financing and partnerships.
• CHMP maintained its negative opinion on MaaT013’s conditional marketing application; MaaT Pharma proposed the PHOENIX Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260929450566) on September 29, 2026, and is solely responsible for the information contained therein.